Clinical trials: High-Risk Localized Prostate Cancer
Cancer of Prostate
Dynamic Focusing Evaluation for Prostate Cancer Treatment
Define the best acoustic parameters for the dynamic focusing HIFU transducer in the treatment of localized Prostate Cancer.
- Trial name
- FOC/DYN (NCT03632980)
- Testing
- "Ablatherm Foc/Dyn" or "Focal One" HIFU treatment
- Where
- France
- Volunteers
- 180 people
- Sponsor
- EDAP TMS S.A.
Prostate Cancer
Trial of Hypofractionated IMRT Boost Versus Conventional IMRT Boost for Localized High Risk Prostate Cancer
Hypofractionation: 48 Gy in 25 fractions to pelvic lymph nodes while the prostate receives 68 Gy in 25 fractions concomitantly. Standard Fractionation: pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23…
- Trial name
- RCT-PHART2 (NCT04239599)
- Testing
- Hypofractionated IMRT Radiation treatment
- Volunteers
- 178 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer.
The aim of the registry is to gather real-life data to evaluate the clinical performance and safety of medical devices in patients who have been treated with HIFU thank to the Focal One device for their prostate cancer.
- Trial name
- One registry (NCT07645872)
- Where
- 5 sites in France
- Volunteers
- 3,000 people
- Sponsor
- EDAP TMS S.A.
Prostate Cancer, Prostate Cancer (Diagnosis)
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma
- Trial name
- LUTACT (NCT07054346)
- Testing
- 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Thomas Hope
Prostate Cancer, Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen
Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging
Trans-perineal focal laser ablation represents a promising alternative focal therapy option for patients with low-risk or favorable intermediate risk prostate cancer.
- Trial name
- NCT05826470
- Testing
- TRANBERG®|Thermal Therapy System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Genesis Research LLC
Prostate Cancer
ES-HIFU, Prospective Data Collection of Patients Treated With Partial Gland HIFU Ablation for Prostate Cancer
The objective of this study is to evaluate the clinical effectiveness and safety of treatment of prostate cancer in patients who have received a focal HIFU treatment using the Focal One medical device.
- Trial name
- ES-HIFU (NCT06375629)
- Testing
- FocalOne
- Where
- 5 sites in Spain
- Volunteers
- 14 people
- Sponsor
- EDAP TMS S.A.
Prostate Cancer
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells.
- Trial name
- NCT06347705
- Testing
- 2141-V11 Antibody
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
The percentage of malignant prostate tumors detected very early is constantly increasing and the number of well differentiated tumors, with small volume and low risk of progression increases.
- Trial name
- HIFUSA (NCT03531099)
- Testing
- treatment with focal HIFU, PSA dosage, MRI
- Where
- 14 sites in France
- Volunteers
- 108 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00225420)
- Testing
- docetaxel, leuprolide acetate, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer
This pilot randomized, single-blind, placebo-controlled study evaluates the feasibility, safety, and preliminary biological activity of neoadjuvant intraprostatic onabotulinumtoxinA (BOTOX®) administered before radical…
- Trial name
- NCT07796490
- Testing
- OnabotulinumtoxinA (BOTOX®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Prostatic Neoplasms
Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
The primary objective of this trial is to determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metastatic disease results in prolonged biochemically recurrence-free survival after…
- Trial name
- ADAM (NCT04295447)
- Testing
- Standard of care, Apalutamide 60Mg Tab
- Where
- 21 sites in Austria, Germany
- Volunteers
- 190 people
- Sponsor
- Universität Münster
Prostate Cancer, HDR
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR) brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.
- Trial name
- NCT04645810
- Testing
- High-Dose-Rate Brachytherapy
- Where
- United States
- Sponsor
- University of Rochester
Prostate Cancer
A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer
This trial is designed as a randomized two-arm (LDE225 vs. observation groups) open-label prospective clinical trial in men with localized high-risk prostate cancer undergoing radical prostatectomy.
- Trial name
- LDE225 (NCT02111187)
- Testing
- LDE225
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
High Risk Prostate Carcinoma
Towards Optimal Treatment for High Risk Prostate Cancer
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.
- Trial name
- HYPOPRIME (NCT06204341)
- Testing
- HYPOPRIME treatment
- Where
- Netherlands
- Volunteers
- 207 people
- Sponsor
- Haaglanden Medical Centre
Adenocarcinoma of Prostate, Progression of Prostate Cancer
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical progression-free survival in patients with…
- Trial name
- PEACE2 (NCT01952223)
- Testing
- Cabazitaxel, Pelvic radiotherapy, prostate radiotherapy
- Where
- France
- Volunteers
- 761 people
- Sponsor
- UNICANCER
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to other parts of the body (localized).
- Conditions
- Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT04253483
- Testing
- High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer, Prostate Adenocarcinoma
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate…
- Trial name
- NCT04486755
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Maryland, Baltimore
Prostate Cancer
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy.
- Trial name
- NCT03886493
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostatic Neoplasms, Genital Neoplasms, Male
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI…
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
- Trial name
- NCT04461509
- Testing
- 18F-PSMA
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Alessandro D'Agnolo